Healthy scents: microbial volatiles as new frontier in antibiotic research?

Mariana Avalos[1], Gilles P. van Wezel[1,2], Jos M. Raaijmakers[1,2], Paolina Garbeva[2*].

[1]Institute of Biology, Leiden University, Sylviusweg 72, 2333 BE Leiden, The Netherlands.

[2]Netherlands Institute of Ecology, Droevendaalsesteeg 10, 6708 PB Wageningen, The Netherlands.

* Corresponding author: p.garbeva@nioo.knaw.nl

ABSTRACT

Microorganisms represent a large and still resourceful pool for the discovery of novel compounds to combat antibiotic resistance in human and animal pathogens. The ability of microorganisms to produce structurally diverse volatile compounds has been known for decades, yet their biological functions and antimicrobial activities have only recently attracted attention. Various studies revealed that microbial volatiles can act as infochemicals in long-distance cross-kingdom communication as well as antimicrobials in competition and predation. Here, we review recent insights into the natural functions and modes of action of microbial volatiles and discuss their potential as a new class of antimicrobials and modulators of antibiotic resistance.

INTRODUCTION

The problem of antimicrobial resistance

The discovery and use of antibiotics to treat infectious diseases has dramatically affected human life spans. Nevertheless, the increasing use of antibiotics has led to a rapid acquisition of antibiotic resistance by pathogenic microorganisms [1,2] as was already predicted by Alexander Fleming shortly after he discovered penicillin [3]. The threat of the increased frequency of antibiotic resistance is further augmented by the reduced interest and efforts of the pharmaceutical industry to discover and develop novel antibiotics [4-6]. Therefore, scientists are taking the lead in finding new strategies to identify new antibiotics to turn the tide of antibiotic-resistance[7]. In particular, we need to expand the chemical space of bioactive molecules with different modes of action and for which resistance development is less likely to occur. To date, the attention of industrial screening efforts has been almost exclusively directed at canonical antibiotic classes such as polyketides (PKS), nonribosomal

(NRPS) and ribosomal (RiPP) peptide antibiotics, β-lactams and aminoglycosides. However, there is a major and highly diverse class of natural products that has been largely ignored by the pharmaceutical industry, namely the volatile compounds. Research on microbial volatiles is an emerging field with immense potential for both human, animal and plant health [8-11]. Here, we provide a brief and up-to-date overview of recent studies concerning the natural functions of microbial volatiles with a specific focus on volatiles that have antimicrobial activity or that act as modulators of antimicrobial resistance.

Chemical diversity and natural functions of microbial volatile compounds (MVCs)

Bacteria and fungi release a plethora of organic and inorganic volatile compounds, small molecules with low molecular weight and high vapour pressure. These physicochemical properties enable MVCs to diffuse more easily, allowing dispersal over longer distances than other microbial metabolites. A decade ago, the excellent review by Schulz and Dickschat [12] on microbial volatiles marked the rise of this emerging and exciting research field of natural product chemistry. Since then, numerous structurally diverse MVCs produced by marine and terrestrial microorganisms have been described [13,14]. MVCs belong to diverse chemical classes, including alkanes, alkenes, alcohols, esters, ketones, terpenoids, sulfur-containing compounds and a range of small inorganic compounds. Moreover, within these classes there appears to be an enormous chemical diversity of MVCs that remains to be discovered as exemplified by the terpenes sodorifen [15] and pristinol [16]. MVCs may be unique to a single phylogenetic group or even species, which also allows the use of MVCs for chemotaxonomic purposes [17] and for the selective detection of pathogens in both indoor and outdoor environments [18]. For example, VCs produced by *M. tuberculosis* help to detect the pulmonary infection and asses the efficacy of treatment [19].

MVCs play important ecological roles in intra- and inter-kingdom interactions [20 [21]. Activities reported for MVCs include modulation of growth, motility, virulence and biofilm formation as well as production of specialized metabolites (e.g. toxins), antibiotic resistance and spore germination in competing microorganisms (i.e. bacteria, fungi) [22-27]. For example, some *Streptomyces* species surpass obstacles by so-called 'explorer cells', whereby they colonize new areas in the face of competition induced by the biogenic volatile trimethylamine [28]. The skin-borne *Staphyloccoccus schleiferi* produces schleiferons A and B that modulate the skin microbiome possibly by inhibiting the growth of Gram-positive bacteria and by interfering with prodiginines production [26]. Plants also respond to and utilize MVCs leading to growth promotion or inhibition, induced systemic resistance or alteration of the plant metabolome [11,29,30]. Recent studies further point to other intriguing ecological roles of MVCs in cross-kingdom interactions. For example, ammonia produced by bacteria promotes the symbiosis between a fungus and a beetle by regulating the consumption sequence of the carbon sources pinitol and glucose [31]. Other studies indicated that volatiles from *Bacillus subtilis Pseudomonas fluorescens*, *Serratia odorifera*, and *Xanthomonas campestris* act as infochemicals disclosing a food source to bacterial predators, whereby the nematode *Caenorhabditis elegans* responded by crossing a 3-cm plastic barrier presumably to feed on the bacteria [9]. In contrast, MVCs like acetaldehyde, cyclohexene and dimethyl disulfide, were reported to reduce the motility of nematodes [32]. Recent studies in our labs further revealed that terpenes from *Collimonas* may act as a defense mechanism against protozoan predation [21]. Also the terpene geosmin produced by *Streptomyces* and other bacteria has been proposed to be multifunctional as a signaling molecule involved in sporulation of the producing strain [33] and as a deterrent in food for *Drosophila* flies [34]. For more comprehensive overviews of other natural roles of MVCs in intra- and interspecific

interactions and cross-kingdom communication, we refer to several recent reviews [9,14,35-39].

Microbial volatile compounds as antimicrobials

MVCs can have significant inhibitory effects on the growth or development of other microorganisms (Figure 2). The activity spectrum of MVCs appears to be as diverse as their chemistry. Most of the studies to date have focused on antifungal activities of MVCs and only a few have reported their antibacterial properties. Examples include: the hormone-like γ-butyrolactones with broad spectrum activity against bacteria, fungi and yeast [13]; furfuryl isovalerate that inhibits growth of Gram-positive and Gram-negative bacteria, and acts as a quorum quencher in Gram-negative bacteria [13]; pyrazines (2,5-bis (1-methylethyl)-pyrazine), produced by *Paenibacillus* in interaction with *Burkholderia* [40], with activity against human pathogenic bacteria like *Escherichia. coli*, *Staphylococcus aureus* and the yeast *Candida albicans*. Interestingly, only few studies to date have looked into the antibacterial activities of MVCs produced by actinobacteria (Figure 2), the most prolific producers of known antibiotics, anticancer, antifungal, immunosuppressant and herbicidal compounds [41,42]. Preliminary experiments conducted in our labs suggest that the role of actinobacterial MVCs as antibiotics has been grossly underestimated. Our experiments indicated that approximately 15% of all actinobacteria species tested (N=200) can inhibit the growth of *Bacillus subtilis* or *Escherichia coli* in an experimental setup where the actinobacteria were physically separated from the target (Avalos et al. unpublished data). Intriguingly, those actinobacterial strains that produce volatiles that inhibit the growth of the Gram-positive *B. subtilis* did not inhibit growth of the Gram-negative *E.coli* and *vice versa*, suggesting that actinobacterial MVCs exhibit different modes of action.

The antimicrobial activity of MVCs can be further enhanced via synergy with 'soluble' antibiotics. For example, pre-treating antibiotic-resistant bacteria with the terpene eugenol lowered the minimal inhibitory concentration (MIC) such that they became antibiotic sensitive again [43]. Similarly, phenylpropanoids such as β- cinnamic and ferulic acid, conferred sensitivity to amikazin, erythromycin and vancomycin [43]. A mixture of the monoterpenes γ-terpinene, 1S-α-pinene, β-pinene and β-myrcene produced by *Collimonas pratensis* inhibited growth of *S. aureus* and *E. coli* [44]. Additionally, essential oil components such as limonene, sabinene, α-pinene, thymol and carvacrol have been shown to have potential as enhancers of anti-tuberculosis drugs like ethambutol, rifampicin and isoniazid [45].

Modes of action of MVCs

Despite the observations that many MVCs have antimicrobial activity, only few studies provided insight into their modes of action. Pentalenolactone is an example with a specific intracellular target; it impedes glycolysis by inhibiting glyceraldehyde-3-phosphate dehydrogenase (GAPDH) [46]. Another example comes from *Muscodor albus*, a fungus that produces an antimicrobial blend of volatiles [47] that appears to operate by causing DNA damage; *E. coli* cells became particularly sensitive to these MVCs when they lack the enzymes (e.g. RecA) for DNA repair [48]. Another mode of action proposed is the modification of membrane fluidity/permeability by MVCs, allowing their entry into the cell or causing increased leakage of intracellular materials [49]. This mode of action might be widespread among MVCs from different microbial families. For example, VCs from yeasts such as 3-methyl-1-butanol disrupt the fungal membrane by increasing the peroxidation levels of membrane lipids, thereby causing a non-selective permeability of the plasma membrane [50]. Other modes of action comprise the interference of MVCs with cell-to-cell communication or

quorum sensing. The aforementioned schleiferon A and B inhibit quorum sensing, thereby reducing the expression of prodigiosin and bioluminescence in Gram-negative bacteria [26]. Another well-studied example is the diffusible signal factor DSF (cis-11-methyl-2-dodecenoic acid) which modulates the virulence factors in *Xanthomonas campestris* [51,52]. In *B. subtilis*, DSF-family signals significantly decreased the transcription of drug efflux systems and biofilm formation [53]. Homologs occur in many bacteria. One example is *Stenotrophomonas maltophilia*, a Gram-negative bacterium that is found ubiquitously in different environments, including nosocomial infections where it affects biofilm formation in *Pseudomonas aeruginosa*, a lung pathogen associated with cystic fibrosis [54,55].

MVCs as modulators of antibiotic resistance

An important activity of MVCs in the light of this review is their ability to modulate antibiotic resistance. Recently, Groenhagen et al. [56] demonstrated that the volatiles 1-methylthio-3-pentanone and o-aminoacetophenone from *Burkholderia ambifaria* increased resistance of *E. coli* to aminoglycoside antibiotics like gentamicin and kanamycin. Trimethylamine (TMA) modified resistance to tetracycline by increasing the pH and lowering the transport of tetracycline inside the cell due to changes in transmembrane pH and proton motive force [57]. Slow-growing cells present in a normal growing population, also referred to as persister cells or persisters, evolve tolerance to antibiotics and other environmental stresses. Recently, a link was established between persistence and a toxin-antitoxin system. High persistence (*hip*) mutants exhibited significant survival after treatment with cell wall inhibitors. The mutations were mapped to a toxin-antitoxin locus (*hipBA*). In this example, the toxin HipA inactivates glutamyl-tRNA synthetase by phosphorylation, thereby inhibiting cell growth [58,59]. The anti-toxin HipB is a transcriptional repressor that neutralizes HipA

and regulates *hipBA* expression [60,61]. Microarray data of *E. coli* exposed to VCs emitted by *B. subtilis* showed induction of the expression of *hipA* and *hipB*, thereby inducing resistance [24,62]. Specifically, 2, 3-butanedione and glyoxylic acid produced by *B. subtilis* enhance resistance to ampicillin and tetracycline in *E. coli* through *hipBA* [24]. 2-Aminoacetophenone (2-AA) produced by *P. aeruginosa* regulates quorum sensing and also stimulates persister cell formation. The long-range effect of this volatile also influenced persister cell formation in pathogenic bacteria belonging to a different genus that do not produce 2-AA, like *Acinetobacter baumanii* [25]. Interestingly, microorganisms may also 'eavesdrop' the signalling molecules produced by other microorganisms, thereby taking advantage of their effect. As an example, *Pseudomonas putida* recognizes indole produced by *E. coli*, which induced the *Pseudomonas* TtgGHI antibiotic efflux pump allowing its growth in the presence of ampicillin [63].

Besides organic MVCs, it is becoming clear that small inorganic MVCs (such as hydrogen cyanide (HCN)) can have a major effect on antibiotic resistance. We propose that this is a general phenomenon and to exemplify our proposition we discuss three molecules here, hydrogen sulphide (H_2S), nitric oxide (NO) and ammonia (NH_3). H_2S and NO have overlapping activities and play an important role in the protection against oxidative stress and against antibiotics. Interference with H_2S production by *Bacillus anthracis*, *P. aeruginosa*, *S. aureus*, and *E. coli* rendered these human pathogenic bacteria sensitive to a range of different antibiotics, which could be reversed to resistance by adding exogenous H_2S [64]. Interestingly, H_2S provided protection against many classes of antibiotics targeting DNA, RNA, cell wall or protein biosynthesis[64]. These modulating activities have also been attributed to nitric oxide (NO), mainly due to the pioneering work of Gusarov and Nudler [65-68]. NO is produced from arginine by nitric oxide synthases (bNOS) that are present in

many Gram-positive bacteria. NO was first recognized as being critical for the survival of bacteria such as *Bacillus anthracis* against oxidative stress and survival in macrophages [65,67]. However, NO also directly protected bacteria against a broad spectrum of antibiotics [66,68]. In nature, this trait likely evolved to allow NO-producers to share their habitat with other antibiotic-producing species [66]. *B. subtilis* cells producing NO are able to grow in the presence of *P. aeruginosa* producing the toxin PYO [66]. Similarly, *B. subtilis* and *S. aureus* grow in the presence of cefuroxime only when producing NO, while *nos* null-mutants cannot [66]. NO-mediated resistance is achieved through direct chemical modification of toxic compounds [66]. The role of NO may even go a lot further, as it was shown that the lifespan of the NO non-producing *C. elegans* is expanded significantly when it feeds on NO-producing bacilli, offering a striking new example of symbiosis mediated by a volatile compound [69].

Ammonia (NH_3) generated by the catabolism of aspartate, promotes intracellular accumulation of polyamines modifying *E. coli* membrane permeability thereby increasing resistance to tetracycline [70]. In contrast, exposure to ammonia decreased resistance to kanamycin. This effect could be explained by a higher expression of the polyamine-induced protein OppA, a periplasmic binding protein involved in uptake of aminoglucosides [71]. We have recently established that *E. coli* cells become more resistant to NH_3 by reducing the expression of the regulatory system (*ompR/envZ*) of the major outer membrane porins OmpF & OmpC. These results suggest that porins represent a major point of entry for ammonia (Avalos et al., unpublished data).

Outlook and perspectives

Microorganisms are rich sources of VCs. However, their functions and role as antimicrobial are yet poorly understood. Some MVCs are produced by many different bacterial genera, while

others are unique at the species level providing useful information for microbial chemotaxonomy and detection. Furthermore, some MVCs are only induced during interspecific interactions, suggesting a major role in communication and/or competition.

For most bioactive MVCs the genes involved in biosynthesis and regulation are yet unknown. There is indication that the production of some 'soluble' and volatile compounds is encoded by the same genes, for example blastmycinones and butenolides are derived from the antimycin biosynthetic pathway [72]. Salinisporamide A, an anticancer compound presently undergoing clinical trials is synthesized using previously unknown volatile cyclohexene derivatives as intermediates [73]. Such evidence calls for integrative bioinformatics and systems biology approaches to unravel their biosynthesis and study synergism between soluble and volatile compounds. This should shed more light on how closely related these seemingly different 'worlds' of natural products are.

Examples reviewed here bring attention to the fact that MVCs can serve as a self-defence mechanism for the producer or the community. We firmly believe that the near complete omission of volatile compounds from drug discovery efforts needs to be reconsidered especially at a time where new antibiotic treatments are so desperately needed to counteract antimicrobial resistance. One argument that is often heard is that volatile compounds need to be solubilized before they can be applied. This may be true for topical or IV application, but we would like to point out that some of the diseases that are most difficult to treat such as the lung diseases tuberculosis and cystic fibrosis may be targeted by MVCs . Inhaling MVCs should be considered as a possible therapy in addition to regular antibiotic regimes, taking advantage of their direct and modulating effects described in this review. The information gathered can also be used in the design and development of novel chemical structures and therapies such as the example given by Abed, N. et al., (2015) [74], where they use the natural

terpenes farnesyl and geranyl to design a nano-device that takes advantage of the formation of an environmentally sensitive bond between the terpenes and penicillin helping the delivery of the antibiotics directly into cells.

'Small-talk' molecules like the terpene 3-carene produced under poor-nutrient growth conditions [27] or the pyrazines produced by *Paenibacillus* during its interaction with *Burkholderia* [40] play an important role as infochemicals as they are produced specifically when needed while the smaller inorganic molecules like NH_3 or NO produced in high amounts make a 'loud noise' that is easily perceived by different organisms.

Improving our understanding of the natural roles of volatile compounds in the microbial environment (i.e. learning from nature) would greatly help in the search for novel bioactive molecules for drug development or as biomarkers for clinical and industrial purposes.

REFERENCES

1. Davies J: **Inactivation of antibiotics and the dissemination of resistance genes**. *Science* 1994, **264**:375-382.
2. Wright GD: **Molecular mechanisms of antibiotic resistance**. *Chem Commun* 2011, **47**:4055-4061.
3. Fleming A: **The antibacterial action of a *Penicillium*, with special reference ot their use for the isolation of *B. influenzae*.** *Brit J Exp Pathol* 1929, **10**:226-236.
4. Cooper MA, Shlaes D: **Fix the antibiotics pipeline**. *Nature* 2011, **472**:32.
5. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL: **Drugs for bad bugs: confronting the challenges of antibacterial discovery**. *Nat Rev Drug Discov* 2007, **6**:29-40.
6. Wright GD: **Solving the Antibiotic Crisis**. *ACS Infect Dis* 2015.
7. Kolter R, van Wezel GP: **Goodbye to brute force in antibiotic discovery?** *Nat Microbiol* 2016, **1**:15020.
8. Luhachack L, Nudler E: **Bacterial gasotransmitters: an innate defense against antibiotics**. *Curr Opin Microbiol* 2014, **21**:13-17.
9. Kai M, Haustein M, Molina F, Petri A, Scholz B, Piechulla B: **Bacterial volatiles and their action potential**. *Appl Microbiol Biotechnol* 2009, **81**:1001-1012.
10. Weisskopf L: *The potential of bacterial volatiles for crop protection against phytopathogenic fungi* vol 2. Edited by A. Méndez V. Bajadoz, Spain: Formatex Research Center; 2013.
11. Kanchiswamy CN, Malnoy M, Maffei ME: **Chemical diversity of microbial volatiles and their potential for plant growth and productivity**. *Front Plant Sci* 2015, **6**:151.
12.** Schulz S, Dickschat JS: **Bacterial volatiles: the smell of small organisms**. *Nat Prod Rep* 2007, **24**:814-842.
This is a comprehensive review on bacterial volatiles- biosynthesis and occurrence.
13. Schulz S, Dickschat JS, Kunze B, Wagner-Dobler I, Diestel R, Sasse F: **Biological activity of volatiles from marine and terrestrial bacteria**. *Mar Drugs* 2010, **8**:2976-2987.
14. Piechulla B, Lemfack MC, Kai M: **Effects of discrete bioactive microbial volatiles on plants and fungi**. *Plant, Cell & Environment* 2017, **40**:2042-2067.
15. von Reuß SH, Kai M, Piechulla B, Francke W: **Octamethylbicyclo[3.2.1]octadienes from the Rhizobacterium Serratia odorifera**. *Angewandte Chemie International Edition* 2010, **49**:2009-2010.
16. * Klapschinski TA, Rabe P, Dickschat JS: **Pristinol, a Sesquiterpene Alcohol with an Unusual Skeleton from Streptomyces pristinaespiralis**. *Angewandte Chemie International Edition* 2016, **55**:10141-10144.
The structure of novel sesquiterpene alcohol, (+)-(2S,3S,9R)-pristinol, produced by Streptomyces pristinaespiralis was characterised based on NMR spectroscopy. Extensive isotopic labelling experiments were performed to decipher the EI-MS fragmentation mechanism for pristinol.
17. Cordovez V, Carrion VJ, Etalo DW, Mumm R, Zhu H, van Wezel GP, Raaijmakers JM: **Diversity and functions of volatile organic compounds produced by Streptomyces from a disease-suppressive soil**. *Front Microbiol* 2015, **6**:1081.
18. Bos LDJ, Sterk PJ, Schultz MJ: **Volatile Metabolites of Pathogens: A Systematic Review**. *PLoS Pathogens* 2013, **9**:e1003311.
19. Zetola NM, Modongo C, Matsiri O, Tamuhla T, Mbongwe B, Matlhagela K, Sepako E, Catini A, Sirugo G, Martinelli E, et al.: **Diagnosis of pulmonary tuberculosis and assessment of treatment response through analyses of volatile compound patterns in exhaled breath samples**. *Journal of Infection* 2017, **74**:367-376.
20. Garbeva P, Hordijk C, Gerards S, de Boer W: **Volatile-mediated interactions between phylogenetically different soil bacteria**. *Front Microbiol* 2014, **5**:289.
21. * Schulz-Bohm K, Martín-Sánchez L, Garbeva P: **Microbial Volatiles: Small Molecules with an Important Role in Intra- and Inter-Kingdom Interactions**. *Frontiers in Microbiology* 2017, **8**.

This review summarize the current knowledge on the biological function of microbial volatiles in belowground interactions

22. Chitarra GS, Abee T, Rombouts FM, Dijksterhuis J: **1-Octen-3-ol inhibits conidia germination of Penicillium paneum despite of mild effects on membrane permeability, respiration, intracellular pH, and changes the protein composition**. *FEMS Microbiology Ecology* 2005, **54**:67-75.

23. Cugini C, Calfee MW, Farrow JM, 3rd, Morales DK, Pesci EC, Hogan DA: **Farnesol, a common sesquiterpene, inhibits PQS production in Pseudomonas aeruginosa**. *Mol Microbiol* 2007, **65**:896-906.

24. * Kim KS, Lee S, Ryu CM: **Interspecific bacterial sensing through airborne signals modulates locomotion and drug resistance**. *Nat Commun* 2013, **4**:1809.

The work reveals the role of volatiles in interspecies interaction between E. coli and B. subtilis- effect on gene expression, motility and antibiotic resistance.

25. Que YA, Hazan R, Strobel B, Maura D, He J, Kesarwani M, Panopoulos P, Tsurumi A, Giddey M, Wilhelmy J, et al.: **A quorum sensing small volatile molecule promotes antibiotic tolerance in bacteria**. *PLoS One* 2013, **8**:e80140.

26. Lemfack MC, Ravella SR, Lorenz N, Kai M, Jung K, Schulz S, Piechulla B: **Novel volatiles of skin-borne bacteria inhibit the growth of Gram-positive bacteria and affect quorum-sensing controlled phenotypes of Gram-negative bacteria**. *Systematic and Applied Microbiology* 2016, **39**:503-515.

27. Schmidt R, Etalo DW, de Jager V, Gerards S, Zweers H, de Boer W, Garbeva P: **Microbial Small Talk: Volatiles in Fungal−Bacterial Interactions**. *Frontiers in Microbiology* 2015, **6**:1495.

28. *Jones SE, Ho L, Rees CA, Hill JE, Nodwell JR, Elliot MA: **Streptomyces exploration is triggered by fungal interactions and volatile signals**. *Elife* 2017, **6**.

The work provides evidence that volatiles can act as long-range communication signals capable of propagating morphological switches in Streptomyces

29. Kai M, Crespo E, Cristescu SM, Harren FJ, Francke W, Piechulla B: **Serratia odorifera: analysis of volatile emission and biological impact of volatile compounds on Arabidopsis thaliana**. *Appl Microbiol Biotechnol* 2010, **88**:965-976.

30. Park YS, Dutta S, Ann M, Raaijmakers JM, Park K: **Promotion of plant growth by Pseudomonas fluorescens strain SS101 via novel volatile organic compounds**. *Biochem Biophys Res Commun* 2015, **461**:361-365.

31. Zhou F, Xu L, Wang S, Wang B, Lou Q, Lu M, Sun J: **Bacterial volatile ammonia regulates the consumption sequence of d-pinitol and d-glucose in a fungus associated with an invasive bark beetle**. *The Isme Journal* 2017, **11**:2809.

32. Gu Y-Q, Mo M-H, Zhou J-P, Zou C-S, Zhang K-Q: **Evaluation and identification of potential organic nematicidal volatiles from soil bacteria**. *Soil Biology and Biochemistry* 2007, **39**:2567-2575.

33. Schöller CEG, Gürtler H, Pedersen R, Molin S, Wilkins K: **Volatile Metabolites from Actinomycetes**. *Journal of Agricultural and Food Chemistry* 2002, **50**:2615-2621.

34. Stensmyr Marcus C, Dweck Hany KM, Farhan A, Ibba I, Strutz A, Mukunda L, Linz J, Grabe V, Steck K, Lavista-Llanos S, et al.: **A Conserved Dedicated Olfactory Circuit for Detecting Harmful Microbes in Drosophila**. *Cell* **151**:1345-1357.

35. Schmidt R, Cordovez V, de Boer W, Raaijmakers J, Garbeva P: **Volatile affairs in microbial interactions**. *ISME J* 2015, **9**:2329-2335.

36. **Effmert U, Kalderas J, Warnke R, Piechulla B: **Volatile mediated interactions between bacteria and fungi in the soil**. *J Chem Ecol* 2012, **38**:665-703.

This work summarizes morphological and phenotypical alterations that occur in the organisms due to the presence of microbial volatiles.

37. Audrain B, Farag MA, Ryu CM, Ghigo JM: **Role of bacterial volatile compounds in bacterial biology**. *FEMS Microbiol Rev* 2015, **39**:222-233.

38. Junker RR, Tholl D: **Volatile Organic Compound Mediated Interactions at the Plant-Microbe Interface**. *Journal of Chemical Ecology* 2013, **39**:810-825.

39. Kai M, Effmert U, Piechulla B: **Bacterial-Plant-Interactions: Approaches to Unravel the Biological Function of Bacterial Volatiles in the Rhizosphere**. *Frontiers in Microbiology* 2016, **7**:108.

40. Tyc O, de Jager VCL, van den Berg M, Gerards S, Janssens TKS, Zaagman N, Kai M, Svatos A, Zweers H, Hordijk C, et al.: **Exploring bacterial interspecific interactions for discovery of novel antimicrobial compounds**. *Microbial Biotechnology* 2017, **10**:910-925.

41. Barka EA, Vatsa P, Sanchez L, Gavaut-Vaillant N, Jacquard C, Meier-Kolthoff J, Klenk HP, Clément C, Oudouch Y, van Wezel GP: **Taxonomy, physiology, and natural products of the *Actinobacteria***. *Microbiol Mol Biol Rev* 2016, **80**:1-43.

42. Berdy J: **Thoughts and facts about antibiotics: where we are now and where we are heading**. *J Antibiot (Tokyo)* 2012, **65**:385-395.

43. Hemaiswarya S, Doble M: **Synergistic interaction of eugenol with antibiotics against Gram negative bacteria**. *Phytomedicine* 2009, **16**:997-1005.

44. Song C, Schmidt R, de Jager V, Krzyzanowska D, Jongedijk E, Cankar K, Beekwilder J, van Veen A, de Boer W, van Veen JA, et al.: **Exploring the genomic traits of fungus-feeding bacterial genus Collimonas**. *BMC Genomics* 2015, **16**:1103.

45. Sieniawska E, Swatko-Ossor M, Sawicki R, Skalicka-Woźniak K, Ginalska G: **Natural Terpenes Influence the Activity of Antibiotics against Isolated Mycobacterium tuberculosis**. *Medical Principles and Practice* 2017, **26**:108-112.

46. Tetzlaff CN, You Z, Cane DE, Takamatsu S, Omura S, Ikeda H: **A Gene Cluster for Biosynthesis of the Sesquiterpenoid Antibiotic Pentalenolactone in Streptomyces avermitilis**. *Biochemistry* 2006, **45**:6179-6186.

47. Strobel GA, Dirkse E, Sears J, Markworth C: **Volatile antimicrobials from Muscodor albus, a novel endophytic fungus**. *Microbiology* 2001, **147**:2943-2950.

48. Alpha CJ, Campos M, Jacobs-Wagner C, Strobel SA: **Mycofumigation by the volatile organic compound-producing Fungus Muscodor albus induces bacterial cell death through DNA damage**. *Appl Environ Microbiol* 2015, **81**:1147-1156.

49. Trombetta D, Castelli F, Sarpietro MG, Venuti V, Cristani M, Daniele C, Saija A, Mazzanti G, Bisignano G: **Mechanisms of antibacterial action of three monoterpenes**. *Antimicrob Agents Chemother* 2005, **49**:2474-2478.

50. Dalilla Carvalho Rezende MBF, Simone Cristiane Brand, Silvia Blumer and Sérgio Florentino Pascholati: **Antimicrobial activity of volatile organic compounds and their effect on lipid peroxidation and electrolyte loss in Colletotrichum gloeosporioides and Colletotrichum acutatum mycelia**. *African Journal of Microbiology Research* 2015, **9**:1527-1535.

51. Barber CE, Tang JL, Feng JX, Pan MQ, Wilson TJ, Slater H, Dow JM, Williams P, Daniels MJ: **A novel regulatory system required for pathogenicity of Xanthomonas campestris is mediated by a small diffusible signal molecule**. *Mol Microbiol* 1997, **24**:555-566.

52. Wang L-H, He Y, Gao Y, Wu JE, Dong Y-H, He C, Wang SX, Weng L-X, Xu J-L, Tay L, et al.: **A bacterial cell–cell communication signal with cross-kingdom structural analogues**. *Molecular Microbiology* 2004, **51**:903-912.

53. Deng Y, Lim A, Lee J, Chen S, An S, Dong Y-H, Zhang L-H: **Diffusible signal factor (DSF) quorum sensing signal and structurally related molecules enhance the antimicrobial efficacy of antibiotics against some bacterial pathogens**. *BMC Microbiology* 2014, **14**:51-51.

54. Graff GR, Burns JL: **Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis**. *Chest* 2002, **121**:1754-1760.

55. Berg G, Eberl L, Hartmann A: **The rhizosphere as a reservoir for opportunistic human pathogenic bacteria**. *Environ Microbiol* 2005, **7**:1673-1685.

56. Groenhagen U, Baumgartner R, Bailly A, Gardiner A, Eberl L, Schulz S, Weisskopf L: **Production of bioactive volatiles by different Burkholderia ambifaria strains**. *J Chem Ecol* 2013, **39**:892-906.

57. Letoffe S, Audrain B, Bernier SP, Delepierre M, Ghigo JM: **Aerial exposure to the bacterial volatile compound trimethylamine modifies antibiotic resistance of physically separated bacteria by raising culture medium pH**. *MBio* 2014, **5**:e00944-00913.

58. Germain E, Castro-Roa D, Zenkin N, Gerdes K: **Molecular mechanism of bacterial persistence by HipA**. *Mol Cell* 2013, **52**:248-254.

59. Kaspy I, Rotem E, Weiss N, Ronin I, Balaban NQ, Glaser G: **HipA-mediated antibiotic persistence via phosphorylation of the glutamyl-tRNA-synthetase**. *Nat Commun* 2013, **4**:3001.

60. Schumacher MA, Piro KM, Xu W, Hansen S, Lewis K, Brennan RG: **Molecular mechanisms of HipA-mediated multidrug tolerance and its neutralization by HipB**. *Science* 2009, **323**:396-401.

61. Page R, Peti W: **Toxin-antitoxin systems in bacterial growth arrest and persistence**. *Nat Chem Biol* 2016, **12**:208-214.

62. Schumacher MA, Balani P, Min J, Chinnam NB, Hansen S, Vulic M, Lewis K, Brennan RG: **HipBA-promoter structures reveal the basis of heritable multidrug tolerance**. *Nature* 2015, **524**:59-64.

63. Molina-Santiago C, Daddaoua A, Fillet S, Duque E, Ramos J-L: **Interspecies signalling: Pseudomonas putida efflux pump TtgGHI is activated by indole to increase antibiotic resistance**. *Environmental Microbiology* 2014, **16**:1267-1281.

64. Shatalin K, Shatalina E, Mironov A, Nudler E: **H2S: a universal defense against antibiotics in bacteria**. *Science* 2011, **334**:986-990.

65. Gusarov I, Nudler E: **NO-mediated cytoprotection: Instant adaptation to oxidative stress in bacteria**. *Proceedings of the National Academy of Sciences of the United States of America* 2005, **102**:13855-13860.

66. Gusarov I, Shatalin K, Starodubtseva M, Nudler E: **Endogenous nitric oxide protects bacteria against a wide spectrum of antibiotics**. *Science* 2009, **325**:1380-1384.

67. Shatalin K, Gusarov I, Avetissova E, Shatalina Y, McQuade LE, Lippard SJ, Nudler E: **Bacillus anthracis-derived nitric oxide is essential for pathogen virulence and survival in macrophages**. *Proceedings of the National Academy of Sciences* 2008, **105**:1009-1013.

68. van Sorge NM, Beasley FC, Gusarov I, Gonzalez DJ, von Kockritz-Blickwede M, Anik S, Borkowski AW, Dorrestein PC, Nudler E, Nizet V: **Methicillin-resistant Staphylococcus aureus bacterial nitric-oxide synthase affects antibiotic sensitivity and skin abscess development**. *J Biol Chem* 2013, **288**:6417-6426.

69. Gusarov I, Gautier L, Smolentseva O, Shamovsky I, Eremina S, Mironov A, Nudler E: **Bacterial nitric oxide extends the lifespan of *C. elegans***. *Cell* 2013, **152**:818-830.

70. *Bernier SP, Letoffe S, Delepierre M, Ghigo JM: **Biogenic ammonia modifies antibiotic resistance at a distance in physically separated bacteria**. *Mol Microbiol* 2011, **81**:705-716.

This work demonstrates that exposure to ammonia generated by the catabolism of l-aspartate increases the level of intracellular polyamines, in turn leading to modifications in membrane permeability to different antibiotics as well as increased resistance to oxidative stress.

71. Kashiwagi K, Miyaji A, Ikeda S, Tobe T, Sasakawa C, Igarashi K: **Increase of sensitivity to aminoglycoside antibiotics by polyamine-induced protein (oligopeptide-binding protein) in Escherichia coli**. *Journal of Bacteriology* 1992, **174**:4331-4337.

72. Riclea R, Aigle B, Leblond P, Schoenian I, Spiteller D, Dickschat JS: **Volatile lactones from streptomycetes arise via the antimycin biosynthetic pathway**. *Chembiochem* 2012, **13**:1635-1644.

73. Groenhagen U, Leandrini De Oliveira AL, Fielding E, Moore BS, Schulz S: **Coupled Biosynthesis of Volatiles and Salinosporamide A in Salinispora tropica**. *Chembiochem* 2016, **17**:1978-1985.

74. Abed N, Saïd-Hassane F, Zouhiri F, Mougin J, Nicolas V, Desmaële D, Gref R, Couvreur P: **An efficient system for intracellular delivery of beta-lactam antibiotics to overcome bacterial resistance**. *Scientific Reports* 2015, **5**:13500.

Figure 1. Examples of MVCs with antimicrobial activity

Figure 2. Chemical classes of volatile compounds released by bacteria. Highlighted in purple are the VCs identified in *Streptomyces* strains. Zoomed compounds in green correspond to the widespread terpene geosmin (non-active as antibiotic) and ammonia (active as antimicrobial). At the center two-compartment plates: (1) *Streptomyces* strain (left L) producing high amount of ammonia inhibiting the growth of *E. coli* (right R) and (2) *Streptomyces* strain (left L) producing geosmin not inhibiting the growth of *E. coli* (right R)

Figure 3. MVCs modes of action as antimicrobials and modulators of antibiotic resistance.